- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Culver City Today
By the People, for the People
ImmunityBio Reports Record Q1 2026 Revenue
Net product revenue increased nearly 2.7 times year-over-year to $44 million.
Apr. 9, 2026 at 5:48pm
Got story updates? Submit your updates here. ›
ImmunityBio's record Q1 2026 revenue reflects the company's ability to successfully commercialize cutting-edge biotechnology solutions.Culver City TodayImmunityBio, a commercial-stage biotechnology company, announced preliminary select operational results for the first quarter of 2026. The company reported that its net product revenue increased nearly 2.7 times year-over-year to a record $44 million.
Why it matters
ImmunityBio's strong financial performance in Q1 2026 demonstrates the company's ability to successfully commercialize its products and grow its business. This is an important milestone for the company as it continues to develop and bring innovative biotechnology solutions to market.
The details
ImmunityBio reported that its net product revenue increased nearly 2.7 times year-over-year to a record $44 million in the first quarter of 2026. The company attributed this growth to the successful commercialization of its products and increased demand for its biotechnology solutions.
- ImmunityBio announced the preliminary Q1 2026 results on April 9, 2026.
The players
ImmunityBio, Inc.
A commercial-stage biotechnology company that develops innovative solutions in the fields of immunotherapy and cell therapy.
The takeaway
ImmunityBio's strong financial performance in Q1 2026 highlights the company's ability to successfully commercialize its products and grow its business in the rapidly evolving biotechnology industry. This achievement positions the company for continued success as it works to bring more innovative solutions to market.
